The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2019 | Anti-CD47 antibodies & azacitidine for AML and MDS
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the use of anti-CD47 antibodies in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
